This episode features Dave Rosa, CEO of NeuroOne, a company leading the way in innovative solutions for various neurological disorders. The discussion highlights the significant challenges faced by patients with epilepsy, particularly those whose condition is resistant to medication. Traditional treatment often involves multiple invasive surgeries, placing a significant physical and emotional burden on patients.

NeuroOne has developed a groundbreaking technology that integrates both diagnostic and therapeutic functions into a single device. This innovative approach enables physicians to identify the source of seizures and then immediately proceed with ablation of the affected brain tissue within a single surgical procedure, minimizing patient discomfort and hospital stays.

We explore the strategic partnership with Zimmer Biomet that has been pivotal for NeuroOne's successful market access, helping accelerate commercialization. With additional data insights, and future pharma collaboration opportunities, the future is truly bright for Dave and the team. NeuroOne is helping advance the movement towards personalized medicine, offering hope for improved patient outcomes, a story sure to leave you informed and inspired.

Novosound is a pioneering company in the field of ultrasound technology, with a mission to revolutionize the way we monitor vital signs. Traditional blood pressure monitoring methods, often involving bulky cuffs and infrequent measurements, can be inconvenient and provide limited insights. Novosound aims to address these limitations through their innovative, non-invasive, and continuous blood pressure monitoring solution.

By leveraging advanced thin-film ultrasound technology, Novosound's sensors can be integrated into wearable devices, making it possible to track blood pressure in real-time. This continuous monitoring can provide valuable information to both patients and healthcare providers, enabling early detection of potential health issues and more effective management of conditions like hypertension.

In this episode, we delve deeper into the technology behind Novosound's innovations. Dave Hughes, CEO and founder of Novosound, discusses the academic research foundation of the technology, along with the exciting potential for partners to leverage new capabilities with their wearable application. Dave details the company's strategy for a future where continuous, non-invasive monitoring becomes the norm, a story sure to leave you informed and inspired.

IntelVasc is a medical technology company focused on addressing the significant issue of peripheral arterial disease (PAD). This condition, often undiagnosed, can lead to serious complications like heart attacks and strokes. CEO & co-founder, Andrew Ortega-Verdaguer, joins this episode to discuss how he plans to lead the business from visionary prototype through to market as the team gears up for first FDA discussions early next year.

The company's innovative solution involves a minimally invasive sensor, inserted subcutaneously near to the femoral artery. This sensor, paired with a portable scanner, will enable patients to monitor their vascular health at home. By collecting real-time data on blood flow, the technology can empower patients and clinicians to proactively identify potential issues and intervene early, reducing the risk of major complications.

IntelVasc's technology has the potential to revolutionize the management of PAD. By providing a convenient and reliable method for monitoring vascular health, the company aims to improve patient outcomes, reduce healthcare costs, and enhance the overall quality of life for individuals with this condition. With additional AI and ML opportunities, this is an exciting medtech story sure to keep you informed and inspired.

Epilepsy is a neurological disorder affecting millions worldwide, significantly impacting the quality of life of both patients and their loved ones. Traditional management usually relies heavily on medication, which can have severe side effects. Despite the high prevalence of the condition, there is still a lack of objective data on seizure activity.

EpiWatch CEO, Teresa Prego, joins this episode to discuss their wearable device designed to detect and alert for tonic-clonic seizures. By leveraging Apple Watch technology, EpiWatch provides real-time seizure detection and can alert caregivers, potentially reducing the risk of injury and improving response times. The device also collects valuable data on seizure patterns, enabling clinicians to make more informed treatment decisions.

By partnering with clinicians, pharmaceutical companies, and device manufacturers, EpiWatch can integrate seamlessly with existing healthcare solutions, helping contribute to a broader ecosystem of epilepsy management. With FDA clearance anticipated in 2025, EpiWatch has the potential to revolutionize the way epilepsy is managed, improving the lives of patients and their families, a mission sure to leave you informed and inspired.

Bimal Maharjan, CEO & founder of GutSphere, joins the podcast to discuss the company's mission to empower patients with gastrointestinal (GI) issues. Bimal shares his personal journey with chronic GI conditions, highlighting the challenges patients face, such as embarrassment, lack of education, and difficulty navigating the healthcare system.

GutSphere aims to address these challenges by providing a patient-centric platform that offers personalized education, symptom tracking, and community support. The platform leverages AI technology to provide tailored insights and a user-friendly experience. By combining technology with a deep understanding of patient needs, GutSphere has the potential to revolutionize GI care and improve the lives of millions of people.

As GutSphere is currently in development, the team is focused on building a minimum viable product and gathering user feedback to refine the platform. Tune in so you can learn about Bimal’s gut health mission and how to join the GutSphere community to help build a better solution for all patients to improve their gut health. This is a patient-centric story sure to leave you informed and inspired.

In this episode, we delve into the world of AI-powered healthcare with Shayan Mashatian, the founder of Pingoo.AI. You can learn how this innovative startup is applying AI to tackle a critical healthcare challenge: diabetic foot ulcers.

Shayan highlights the alarming statistics surrounding diabetes and its complications, emphasizing the need for greatly improved patient education and engagement. Pingoo.AI's solution leverages AI to provide personalized education and support for patients, helping them understand their condition and manage it effectively.

Shayan also shares how collaboration between healthcare providers, innovators, and patients, is leading to better AI integration and use of data. By leveraging technology and fostering a community-driven approach, the Pingoo.AI team is working towards a future where diabetes and its complications are better managed and ultimately prevented, a mission sure to leave you informed and inspired.

Novobeing is addressing a significant problem in healthcare: poor patient experience during hospital stays. Their solution involves using virtual reality technology to transport patients to calming environments, helping to reduce stress and anxiety. Beyond the direct benefits to patients, this also aims to improve HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) scores, as patient satisfaction increases.

CEO and co-founder, Sid Desai, shares how their research studies are validating these benefits for hospitals systems, with exciting recent results from Massachusetts General Hospital providing further evidence. The company's initial focus is on patients undergoing stem cell transplant procedures, who often face prolonged hospital stays and isolation. Novobeing’s VR technology offers a way to improve their mental well-being and overall experience.

With several hospital systems already testing Novobeing’s solution, Sid discusses the exciting opportunities, including the potential to reduce pharmacological interventions. As the healthcare industry embraces Medical VR, the vision of fully patient-centered care comes closer to reality. Novobeing is well placed to play a central role in this evolution, meaning this story is sure to leave you informed and inspired.

Prapela is a medical device company focused on improving newborn health. Their primary product is a specially designed mattress that uses gentle vibrations to regulate infant breathing, particularly for babies experiencing apnea of prematurity and neonatal opioid withdrawal syndrome.

CEO & co-founder, John Konsin, joins this episode to share how many newborns, especially premature babies, experience breathing irregularities, including apnea and oxygen desaturation. Prapela's innovative mattress offers a non-invasive solution than can reduce the need for additional interventions while lowering costs for hospitals.

Prapela's market potential is significant, as it addresses a common and serious issue affecting newborn infants. Building on decades of research and recent exciting clinical evidence, the Prapela journey is definitely one to track, be sure to tune in so you can be informed and inspired.